2024年至2032年人類微生物組市場機會、成長動力、產業趨勢分析與預測

2023 年，全球人類微生物組市場價值為 8.424 億美元，預計將經歷顯著成長，2024 年至 2032 年的年複合成長率(CAGR) 為25.7%。不斷提高在健康和疾病管理中發揮重要作用。隨著製藥業擴大採用基於微生物組的療法，市場有望大幅擴張。對個人化醫療的需求以及與微生物組靶向干預相關的治療可能性是推動這一成長的重要因素。對微生物組如何影響人類健康的更深入了解推動了該領域的研究和開發，特別是針對慢性疾病和代謝紊亂患病率上升的情況。

人類微生物組市場依不同的解剖部位進行分類，包括消化道、肺部、生殖腔、皮膚和其他部位。其中，消化道部分所佔佔有率最大，到 2023 年將達到 31.7%。研究越來越關注腸道微生物群失衡的影響，腸道微生物群失衡與各種健康問題有關，包括肥胖和發炎性腸道疾病 (IBD)。市場也按治療和診斷應用進行細分。

治療領域在2023 年佔據64.7% 的市場佔有率，預計到2032 年將實現快速成長。療法。該公司正在積極開發基於微生物組的治療方法，重點關注胃腸道疾病、代謝疾病和免疫相關疾病，其中許多治療方法正在臨床試驗中。

北美在人類微生物組市場中處於領先地位，到2023 年價值將達到2.612 億美元，預計到2032 年複合年成長率為24.9%。以及對微生物組治療的投資不斷增加。隨著更多基於微生物組的療法獲得監管部門的批准，該地區對創新的強力的監管支持、不斷成長的醫療保健支出以及對個性化醫療意識的提高使其能夠實現持續的市場成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 與生活方式相關的疾病負擔日益加重，老年人口不斷增加
    • 增加資助計劃和政府計劃
    • 精準醫療需求不斷成長
    • 監理途徑長、開發成本高
  • 產業陷阱與挑戰
    • 道德和安全問題
• 成長潛力分析
• 監管環境
• 技術景觀
  • 核心技術
  • 鄰近技術
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：人類微生物組市場：依地點分類，2018 年 - 2032 年

• 主要趨勢
• 消化道
• 肺
• 生殖腔
• 皮膚
• 其他網站

第 6 章：人類微生物組市場：依應用分類，2018 - 2032

• 主要趨勢
• 療法
• 診斷

第 7 章：人類微生物組市場：依疾病分類，2018 - 2032

• 主要趨勢
• 傳染病
• 胃腸道疾病
• 內分泌及代謝疾病
• 癌症
• 中樞神經系統失調
• 其他疾病

第 8 章：人類微生物組市場：依產品分類，2018 - 2032

• 主要趨勢
• 藥品
• 益生菌
• 益生元
• 診斷測試
• 其他產品

第 9 章：人類微生物組市場：按地區分類，2018 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
• 拉丁美洲
  • 巴西
  • 墨西哥
• MEA
  • 南非
  • 沙烏地阿拉伯

第 10 章：公司簡介

• Seres Therapeutics
• Enterome
• Second Genome Inc.
• DuPont
• Synthetic Biologics, Inc.
• Synlogic
• Vedanta Biosciences, Inc.
• Metabiomics Corporation
• MICROBIOME THERAPEUTICS LLC
• 4D pharma plc

The Global Human Microbiome Market was valued at USD 842.4 million in 2023 and is projected to experience remarkable growth, with a compound annual growth rate (CAGR) of 25.7% from 2024 to 2032. This surge is largely fueled by the growing recognition of the microbiota's essential role in health and disease management. As the pharmaceutical sector increasingly adopts microbiome-based therapies, the market is poised for substantial expansion. The demand for personalized medicine and the therapeutic possibilities associated with microbiome-targeted interventions are significant factors driving this growth. A deeper understanding of how the microbiome influences human health propels research and development in this field, particularly in response to the rising prevalence of chronic illnesses and metabolic disorders.

The human microbiome market is categorized by various anatomical sites, including the digestive tract, lungs, reproductive cavity, skin, and other locations. Among these, the digestive tract segment held the largest share at 31.7% in 2023. The gut microbiome is crucial for digestion, immune function, and overall well-being, making it a primary focus for microbiome-based therapies. Research is increasingly focused on the effects of imbalances in gut microbiota, which are linked to various health issues, including obesity and inflammatory bowel disease (IBD). The market is also segmented by application into therapeutics and diagnostics.

The therapeutics sector accounted for 64.7% of the market share in 2023 and is anticipated to see rapid growth through 2032. As researchers gain insights into the microbiome's role in numerous diseases, there is a concerted effort to develop therapies that can modulate or restore healthy microbiota. Companies are actively developing microbiome-based treatments focusing on gastrointestinal disorders, metabolic diseases, and immune-related conditions, with many in the pipeline for clinical trials.

North America leads the human microbiome market, achieving a value of USD 261.2 million in 2023, with a projected CAGR of 24.9% through 2032. This dominance can be attributed to major pharmaceutical firms, a robust research infrastructure, and increasing investments in microbiome therapeutics. The region's strong regulatory support for innovation, rising healthcare expenditures, and heightened awareness of personalized medicine positions it for sustained market growth as more microbiome-based therapies gain regulatory approval.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing burden of lifestyle-related diseases and the growing geriatric population
    • 3.2.1.2 Increasing funding initiatives and government program
    • 3.2.1.3 Increasing demand precision medicine
    • 3.2.1.4 Long regulatory pathways and high development costs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Ethical and safety concern
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Human Microbiome Market, By Site, 2018 - 2032 (USD Million)

• 5.1 Key trends
• 5.2 Digestive tract
• 5.3 Lung
• 5.4 Reproductive cavity
• 5.5 Skin
• 5.6 Other sites

Chapter 6 Human Microbiome Market, By Application, 2018 - 2032 (USD Million)

• 6.1 Key trends
• 6.2 Therapeutics
• 6.3 Diagnostics

Chapter 7 Human Microbiome Market, By Disease, 2018 - 2032 (USD Million)

• 7.1 Key trends
• 7.2 Infectious diseases
• 7.3 Gastrointestinal diseases
• 7.4 Endocrine & metabolic diseases
• 7.5 Cancer
• 7.6 Central nervous system disorder
• 7.7 Other diseases

Chapter 8 Human Microbiome Market, By Product, 2018 - 2032 (USD Million)

• 8.1 Key trends
• 8.2 Drugs
• 8.3 Probiotics
• 8.4 Prebiotics
• 8.5 Diagnostic tests
• 8.6 Other products

Chapter 9 Human Microbiome Market, By Region, 2018 - 2032 (USD Million)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
• 9.6 MEA
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia

Chapter 10 Company Profiles

• 10.1 Seres Therapeutics
• 10.2 Enterome
• 10.3 Second Genome Inc.
• 10.4 DuPont
• 10.5 Synthetic Biologics, Inc.
• 10.6 Synlogic
• 10.7 Vedanta Biosciences, Inc.
• 10.8 Metabiomics Corporation
• 10.9 MICROBIOME THERAPEUTICS LLC
• 10.10 4D pharma plc